🔎 Trials Near Me

Hjem › Burkitts lymfom › District of Columbia › Washington

Kliniske studier for Burkitts lymfom i Washington, DC

9 studier for Burkitts lymfom søker deltakere på steder i og rundt Washington (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.

Offisiell studietekst (engelsk)

Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

RekruttererFase 2
  • MedStar Georgetown University Hospital, Washington D.C.
  • Children's National Medical Center, Washington D.C.
  • Walter Reed National Military Medical Center, Bethesda · 7 mi unna
366 Days – 46 Years · Alle kjønn · Oppdatert 2. okt. 2026 · NCT06124157

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies

RekruttererFase 1/2
  • National Institutes of Health Clinical Center, Bethesda · 7 mi unna
Alder 3 til 39 · Alle kjønn · Oppdatert 30. sep. 2026 · NCT05442515

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

RekruttererFase 2
  • MedStar Georgetown University Hospital, Washington D.C.
Alder 18 og eldre · Alle kjønn · Oppdatert 29. sep. 2026 · NCT03739814

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

RekruttererFase 1/2
  • National Institutes of Health Clinical Center, Bethesda · 7 mi unna
Alder 18 til 120 · Alle kjønn · Oppdatert 28. sep. 2026 · NCT03223610

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

RekruttererFase 3
  • American Oncology Partners, PA dba The Center for Cancer and Blood Disorders, Bethesda · 7 mi unna
Alder 18 og eldre · Alle kjønn · Oppdatert 21. sep. 2026 · NCT07648264

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

RekruttererFase 2
  • Children's National Medical Center, Washington D.C.
Alder 1 til 30 · Alle kjønn · Oppdatert 1. sep. 2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

RekruttererFase 3
  • Children's National Medical Center, Washington D.C.
  • Walter Reed National Military Medical Center, Bethesda · 7 mi unna
365 Days – 25 Years · Alle kjønn · Oppdatert 25. aug. 2026 · NCT03959085

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

RekruttererFase 1
  • National Institutes of Health Clinical Center, Bethesda · 7 mi unna
Alder 18 til 120 · Alle kjønn · Oppdatert 25. aug. 2026 · NCT05389423

Burkitts lymfom-studier i andre byer

Andre studier i Washington

Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.